DMPK, Dosage, Bioavailability
7:00 am Registration Opens & Coffee
Lost in Translation: Overcoming the Barriers of in-vitro & in-vivo Action of Cannabinoid- Derived Drugs to Improve Efficacy
8:00 am Meaningful in vitro Data on Cannabinoids: Providing Value to Clinical Study Design
Synopsis
- What is physiological and what’s not in cannabinoid research?
- Discussing the gap between a therapeutic dose and a toxic dose in-vitro
- Understanding the value of standardizing tissue culture assays for cannabinoids
8:30 am Designing Animal Models for Assessing Safety, Tolerability & Efficacy of Cannabinoids in Neurological Diseases
Synopsis
- Exploring appropriate animal models for drug testing
- Testing of efficacy in animal models in neurological disease areas
- Understanding the translational impact of animal model testing
9:00 am Rethinking the Approach to Advancing Cannabinoid-Based Drug Development: A Case Study of Musculoskeletal Pain & Inflammation
Synopsis
- Optimizing cannabinoid-based formulations for topical application
- Challenges with current preclinical models and their translation to human experience
- Using AI and observational data to determine the preclinical pathway
9:30 am Speed Networking
Synopsis
This session is the ideal opportunity to take advantage of face-to-face networking time and understand who is also prioritizing and overcoming challenges within cannabinoidderived drug development.
10:00 am Morning Break & Networking
Synopsis
Grab a coffee and buckle up for the next set of morning presentations. This networking session provides a unique offering of group activities to stimulate creativity, foster productivity and enable discussions amongst cannabinoid experts.
10:30 am Unlocking Cannabinoid-based Drug Development: Combining High Quality APIs, Patient-centric Solutions & Expert Services to Strategically Address Market Challenges & Capitalize on Innovation Opportunities
DMPK: Balancing Potency, Metabolism, Efficacy & Dosage to Achieve Patient Safe & Compliant Cannabinoid Drugs
11:00 am Understanding Cannabinoid Disposition using Structure – Activity based Approaches for Predicting key DMPK Parameters
Synopsis
- Engineering molecules to reduce metabolic clearance
11:30 am Challenges in Cannabinoid-based Formulations from Development to Clinical Translation
Synopsis
- Understand factors controlling cannabinoid absorption
- Strategies to delivery cannabinoids for specific conditions
- Stability and ingredients compatibility with cannabinoids
- Scale up to manufacture
12:00 pm Lunch & Networking
12:15 pm Virtual presentation hosted during lunch: Chemical Probes & Their Relevance for Drug Discovery Programs Targeting the Endocannabinoid System
Synopsis
- Chemical probes are of utmost importance for bringing drugs from the laboratory through the clinic and ultimately to the market
- Chemical probes support and affect all research and discovery phases
- Examples of probes targeting the cannabinoid receptor type-2 (CB2R) and monoacylglycerol lipase (MAGL) will be highlighted
1:00 pm Challenges & Solutions for Testing Contaminants & Adulterants in Cannabis
Synopsis
- A comprehensive approach to protecting the integrity of cannabis drug products and drug substances must include considerations and specifications for impurities – contaminants and adulterants
- This presentation will provide recommendations for creating a thorough testing program to detect impurities in cannabis drug products and drug substances
- We will discuss examples of testing methods that address monitoring and quantifying adulterants and contaminants that meet specified requirements
1:45 pm Improving Cannabidiol for Oral Solid Dosage form Drug Products
Synopsis
- Improving solubility, dissolution and, absorption through co-crystallisation
- Data supporting improving bioavailability and potency of ART12.11 in chronic stress models measuring anxiety, sociability and, cognition
- Gaining composition of matter patent for CBD, how to achieve it and what it enables for R&D investment and exploration beyond orphan drugs and oral solutions
2:15 pm Catalytic Synthesis of Cannabinoids
Synopsis
- Kare (www.karechem.com) is a technology company specializing in the development of new cannabinoid precursors that are efficiently converted into single component and pure cannabinoids using a catalyst
- Our high throughput catalytic process is used to prepare CBD and THC, as well as the rare cannabinoids CBDV, THCV, CBDP, THCP, CBN and many more under mild conditions
- The cannabinoid products are of high chemical and chiral purity and are identical to their plant-derived counterparts
- Our technology enables stability of supply, low cost and control over quality and scalability
2:45 pm Afternoon Break & Networking
Evaluating Polypharmacy: Applications & Interactions of CBD to Disease States & Outcomes
3:30 pm Exploring the therapeutical effects of cannabinoid-derived compounds in multiple indications
Synopsis
– Pharmacodynamic Study of Cannflavin A
– Study on Enhancing the Sustainability of Local Anesthetics with CBDV
– Pharmacodynamic Study of CBD in Oral and Skin Injuries
4:00 pm Scientific Rationale on the Combination of CBD & Statins
Synopsis
- Discussing the synergy between CBD and Statins to prove the benefit and practicalities of how CBD associates with Statins
- Detailing avoidance of mitochondrial oxidative stress, anti-inflammatory, and metabolic competitive inhibition through CBD with Statins
4:30 pm Evidence to Support CBD in Diseases of High Mortality: Rationale for Polypharmacy
Synopsis
- In depth discussion of late breaking data comparing CBD isolate to cannflavins and cannabinoids used in combination in the Tau model of neurodegenerative disease
- Rationale and evidence for the long-term use of cannabinoids use in diseases with high mortality
- Analyzing the nuance of cannabinoid rational polypharmacy, "entourage vs non-tourage"